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OBJECTIVES: High income groups in Pakistan resort to private health care settings 
for consultations and treatment modalities but only 5% of them have Social Health 
insurance coverage. As 77% of medicine expenditures are out-of-pocket payments in 
Pakistan, it is imperative to assess the understanding, perception, and attitude of this 
privileged group towards cost-effective alternatives. METHODS: In order to have an 
in depth evaluation of the issue qualitative methodology was adopted. a combination 
of purposive and snowball sampling was used to conduct face-to-face semi-structured 
interviews, which were then audio-taped, and transcribed verbatim. As sample size in 
qualitative research revolves around the attainment of point of saturation, no new 
themes emerged after the interview of 8 respondents. RESULTS: Thematic content 
analysis identiﬁ ed four major themes; appropriate knowledge of generic medicines, 
negative perception towards generic medicines, negative attitude towards generic 
medicines, and future recommendations which should be directed towards the main-
tenance of quality and efﬁ cacy of generic alternatives. Interestingly, all the respondents 
managed to explain generic medicines with reference to patent expiry. Regarding 
perception all of them expressed negative views and considered quality and safety as 
questionable domains in generic medicines. All the respondents cited negative concerns 
towards generic medicine utilization and harbored the notion that “low cost relates 
compromised quality.” Majority of the respondents expressed that future strategies 
should be directed towards educated high income group to build conﬁ dence for gener-
ics and this should be possible until and unless the local manufacturers in Pakistan 
make themselves compliant with WHO Good Manufacturing Practices (GMP). CON-
CLUSIONS: The respondents showed excellent understanding towards generic medi-
cines. They exhibited negative concerns and attitudes towards generic medicine 
utilization. Still there is room for improvement, provided the conﬁ dence is built in 
consumers regarding generic medicines quality and efﬁ cacy, which in turn will pave 
the way for their quality utilization.
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METFORMIN FOR THE TREATMENT OF CHILDHOOD OBESITY: A 
SYSTEMATIC REVIEW AND META-ANALYSIS
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OBJECTIVES: Childhood obesity associates with signiﬁ cant morbidity and premature 
death; its prevalence has increased greatly during the past three decades; and it is 
recognized as a worldwide public health problem. However, the efﬁ cacy of treatments 
for childhood obesity remains unclear. In recent years the use of metformin, an insulin 
sensitizer, has aroused a great interest for the treatment of obesity in adults. Our aim 
was to assess the efﬁ cacy and safety of metformin for childhood obesity. METHODS: 
Systematic review of literature and meta-analysis of randomized controlled trials in 
obese subjects age ≤19 years without diabetes or other morbidities. Structured elec-
tronic searches of published studies until March 2010 were performed. Changes in 
the Body Mass Index (BMI) were considered our main outcome measure of efﬁ cacy 
whereas metabolic parameters such as insulin levels, glucose, HOMA, lipid proﬁ le and 
leptin levels were considered as secondary outcomes. Safety parameters included 
adverse events and losses from adverse effects. Individual studies were graded using 
published methodologies. Pooled estimates of effect and conﬁ dence intervals were 
derived using a ﬁ xed effects model and tested for heterogeneity. Consistency across 
studies was evaluated by means of the I-square statistic. RESULTS: Seven trials met 
the inclusion criteria. All trials compared metformin with placebo and used behav-
ioural co-interventions. Average follow-up was six months. Though with small sample 
sizes, methodological quality of trials was adequate. Meta-analysis showed that com-
pared to placebo, metformin provided a signiﬁ cant decrease in BMI (−1.90 (−3,−.8). 
No statistical signiﬁ cant differences were found in secondary outcomes. Main adverse 
effects were digestive, no serious adverse events were reported. CONCLUSIONS: 
Available evidence suggests that, added to behavioural interventions, metformin is a 
relatively safe and effective treatment for childhood obesity in the short term. Further 
research with longer follow-up periods is needed to solve this important health issue. 
Partially supported by Spanish National I+D Program.
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OBJECTIVES: Assess the impact of the treatment of urinary disorders of the lower 
urinary tract related to benign prostatic hypertrophy (BPH) using medical treatment 
under actual conditions of use. METHODS: A pragmatic cohort of 420 patients 
treated medically, was followed up for 6 months, using several validated question-
naires: IPSS, MSF4, and SF12. RESULTS: 267 patients treated with Serenoa Repens 
were evaluated, the mean age was 64.3 ± 8.6 years, and on average the diagnosis had 
been made 18 months previously. At 6 weeks, the IPSS was signiﬁ cantly improved in 
this group (P < 0.0001). This improvement in the IPSS score between 6 weeks (11.98 
± 5.11) and inclusion (14.58 ± 5.65) was 2.6 points. An improvement was also 
observed at 3 months. At 6 months, the p-value was also signiﬁ cant (P < 0.0001). The 
improvement in the IPSS score between 6 months (8.20 ± 4.12) and inclusion (14.65 
± 7.01) was 6.6 points. The physical dimension (50.97 ± 6.45 at inclusion) of the SF12 
improved signiﬁ cantly (P < 0.001) from the 6th week (52.63 ± 5.20), an improvement 
that was conﬁ rmed at 6 months (53.21 ± 5.16) (P < 0.001) in comparison with inclu-
sion (49.09 ± 6.58). The mental dimension (50.9 ± 7.04 at inclusion) of the SF12 
improved signiﬁ cantly (P < 0.001) from the 6th week (52.16 ± 7.31), an improvement 
that was conﬁ rmed between 5.45 and 6 months (52.50 ± 6.69) (P < 0.001) in com-
parison with inclusion (47.09 ± 10.82). The MSF4 was unchanged. CONCLUSIONS: 
We observed an improvement in the IPSS score from the 6th week; this statistical 
improvement was conﬁ rmed by a signiﬁ cant clinical improvement in the 6th month. 
This favourable progression is consistent with the improvement observed for both 
dimensions of the SF12.
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OBJECTIVES: Comparison of regulatory rules and procedures for pricing and reim-
bursement of pharmaceuticals between Bulgaria and the Czech Republic (CR). 
METHODS: Medicine laws, health insurance laws, corresponding regulations stating 
the pricing and reimbursement procedures were reviewed. Special emphasis was 
devoted to the requirements for pharmacoeconomic evidences in the procedures. 
RESULTS: Both countries apply the reference pricing system for prescription medi-
cines and the CR is among the 8 reference countries for Bulgaria, while the opposite 
is not the case. In Bulgaria the lowest reference price for ex-factory price setting is 
used, while the CR employs the average among the three lowest prices. There is also 
a regressive margin scale in both countries applied. In Bulgaria margins are stated for 
wholesalers and retailers separately, while in the CR they are negotiated between 
wholesalers and retailers. In both countries health insurance is obligatory. In the CR 
there are 11 insurance companies and in Bulgaria—only one fund. In Bulgaria reim-
bursement is in the form of positive drugs lists. For reimbursement of pharmaceuticals 
in the CR a complex external and internal referencing is employed and evaluation of 
innovativeness is necessary. There are 111 internal therapeutic groups deﬁ ned at the 
4th ATC level (e.g. statins). The reimbursement base is set as the cheapest price of 
medicine in the group in all 27 EU countries. There is a bonus of maximum 30% if 
a medicine shows superiority. In Bulgaria the reimbursement level is deﬁ ned as the 
cheapest price per DDD for every INN. Both countries require pharmacoeconomic 
evidences, but there are guidelines in the CR, while Bulgaria applies only criteria for 
evaluation. CONCLUSIONS: We consider the Czech system more ﬂ exible and provid-
ing freedom for the manufacturers and distributors due to its negotiating practice and 
therapeutic level of reimbursement, but the process is more prolonged.
PIH57
CHALLENGES IN THE ADHERENCE AND ADOPTION OF 
INTERNATIONAL GUIDELINES: A SYSTEMATIC REVIEW OF THE 
ADHERENCE TO THE HEALTH CARE INFECTION CONTROL 
PRACTICES ADVISORY COMMITTEE (HICPAC) GUIDELINES FOR THE 
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OBJECTIVES: One of the most pressing problems faced by health care services is the 
increasing prevalence of antimicrobial resistance to vancomycin, an important anti-
microbial for the treatment of infections caused by gram-positive pathogens in the 
severely ill patient. Inappropriate use of vancomycin encompasses serious public health 
consequences linked to the development of resistant species. In 1995, the HICPAC 
developed guidelines that delineated speciﬁ c criteria for appropriate vancomycin use 
to reduce the improper use of antimicrobials and improve patient safety. Our aim was 
to evaluate and summarize the level of compliance of clinical practices with the 
HICPAC guidelines by assessing the appropriateness of vancomycin therapy for hos-
pitalized critically ill children. METHODS: Systematic review of literature (Jan 1996-
Feb 2010) and meta-analysis of studies performed in subjects aged 0–18 years. 
Structured electronic and manual searches were performed. The main outcome 
measure was the proportion of vancomycin prescribed appropriately according to the 
HICPAC guidelines. Appropriate/inappropriate uses were subdivided into several cat-
egories. Summary rate ratios and conﬁ dence intervals were estimated using a ﬁ xed 
effects model and tested for heterogeneity. Furthermore, we explored the potential 
reasons for non-adherence to guidelines. RESULTS: From 24 candidate studies, 13 
publications met the inclusion criteria. Meta-analysis showed that in only 21% of 
patients (95%CI: 18%–23%), vancomycin prescribing and dispensing practices were 
consistent with the recommendations. Non-adherence to HICPAC guidelines included 
surgical prophylaxis, empirical use and length of therapy. Lack of awareness, lack of 
agreement, lack of outcome expectancy and inertia of previous practice, emerge as 
speciﬁ c reasons for non-adherence. CONCLUSIONS: This study reveals that adher-
ence to international guidelines is far from optimal with a variety of potential barriers 
that undermine the process. Because physician adherence is critical in translating 
recommendations into improved outcomes, there is an urgent need for strategies aimed 
at improving physician compliance with guidelines to optimize antibiotics utilization. 
S upported by the Spanish National I+D Program (STPY 1346/09). 
